Heart failure & cardiomyopathiesCohort study
High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life
- Prospective cohort study
- community-based
- longitudinal
- external replication (Cardiovascular Health Study (CHS))
- Mendelian randomization
- Data analysis February 2022 to June 2023
Authors' conclusion
In this study, the proteins associated with risk of HF and frailty enrich for pathways related to inflammation and fibrosis as well as risk of HFpEF.
Study context
- Population
- Older adults in the community-based Atherosclerosis Risk In Communities (ARIC) cohort (visits 3, 5, 6); external replication in the Cardiovascular Health Study (CHS)ARIC V3
- Participants
- 10,638 adults
- Outcome
- Incident HF hospitalization after V3 and after V5, prevalent frailty at V5 (Fried criteria) and incident frailty between V5 and V6, by plasma protein aptamers (4877, Somascan v4)
Main finding
As reported in the abstract
Proteins associated with HF and frailty
Proteins associated with incident heart failure (HF) after V3 (822 events)
286
Of these, associated with incident HF after V5 (336 events)
83
HF-associated proteins associated with prevalent frailty at V5 (223 cases)
48 of 83
Of these, associated with incident frailty at V6 (152 cases)
18
Observational data: associations, not effects.
Further findings
External replication in CHS
- All 18 proteins associated with both prevalent frailty and incident HF in CHS
Mendelian randomization
- Potential causal effects of several proteins on frailty and HF
Original publication
High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life. JAMA Cardiol. Published 1 July 2024. doi:10.1001/jamacardio.2024.1178
Summarised from the published abstract; every number is checked against it